Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Phase 1

Active, not recruiting

Conditions: Gastric and Gastroesophageal Junction Carcinoma

Interventions: Drug: Atezolizumab
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Tiragolumab

First Posted Date: 2022-02-23

Last Posted Date: 2025-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT05251948

Locations: 🇨🇳
The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China
🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou City, China
🇨🇳
the First Hospital of Jilin University, Changchun, China

and more 9 locations

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: RO7623066
Drug: Olaparib
Drug: Carboplatin

First Posted Date: 2022-02-15

Last Posted Date: 2025-05-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 250

Registration Number: NCT05240898

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Maine, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 12 locations

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis
Primary Progressive Multiple Sclerosis

Interventions: Drug: Ocrelizumab IV
Drug: Ocrelizumab SC
Drug: Dexamethasone given orally
Drug: Methylprednisolone IV
Drug: Desloratadine given orally
Drug: Diphenhydramine IV

First Posted Date: 2022-02-10

Last Posted Date: 2025-05-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 236

Registration Number: NCT05232825

Locations: 🇮🇹
IRCCS Istituto Neurologico Neuromed, Pozzilli, Molise, Italy
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇨🇿
Fakultni nemocnice u sv. Anny, Brno, Czechia

and more 34 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: RO7443904
Drug: Glofitamab
Drug: Obinutuzumab
Drug: Tocilizumab

First Posted Date: 2022-02-02

Last Posted Date: 2024-08-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 53

Registration Number: NCT05219513

Locations: 🇫🇷
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, France
🇮🇹
ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy

and more 6 locations

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Phase 4

Withdrawn

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab

First Posted Date: 2022-01-26

Last Posted Date: 2024-01-23

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT05208840

Locations: 🇷🇺
City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, Russian Federation
🇷🇺
National Center of Socially Significant Diseases, Saint-Petersburg, Sankt Petersburg, Russian Federation

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase 3

Recruiting

Conditions: Neuromyelitis Optica Spectrum Disorder
NMOSD

Interventions: Drug: Satralizumab

First Posted Date: 2022-01-20

Last Posted Date: 2025-06-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT05199688

Locations: 🇺🇸
Children's Hospital Colorado., Denver, Colorado, United States
🇦🇷
Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires, Argentina
🇦🇷
Clinica Universitaria Reina Fabiola, Cordoba, Argentina

and more 5 locations

A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: RO7428731

First Posted Date: 2022-01-12

Last Posted Date: 2025-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT05187624

Locations: 🇺🇸
UCLA Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 5 locations

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Phase 4

Active, not recruiting

Conditions: Severe Hemophilia A
Moderate Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2022-01-06

Last Posted Date: 2025-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 136

Registration Number: NCT05181618

Locations: 🇮🇹
Policlinico Univ. A. Gemelli, Roma, Lazio, Italy
🇮🇹
AOU Careggi, Firenze, Toscana, Italy
🇪🇸
Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruna, Spain

and more 24 locations

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2021-12-29

Last Posted Date: 2024-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 179

Registration Number: NCT05171777

Locations: 🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada
🇮🇹
Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

and more 36 locations

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 3

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Rituximab
Drug: Polatuzumab vedotin
Drug: Gemcitabine
Drug: Tocilizumab
Drug: Oxaliplatin

First Posted Date: 2021-12-29

Last Posted Date: 2025-05-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 242

Registration Number: NCT05171647

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
St. Luke's Hospital, Chesterfield, Missouri, United States
🇺🇸
Ascension Seton Infusion Center, Austin, Texas, United States

and more 50 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy